Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Turkey: A pilot study published in BMC Ophthalmology suggests that a gamified, app-based multimodal visual therapy may offer ...
Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...
“Our findings indicate that the vaccine provided a significant enhanced level of protection against these infections in the ...
The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...
Company expects topline data from the study in 2027WESTLAKE VILLAGE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a ...
TipRanks on MSN
Almirall advances LAD603 phase 2 alopecia trial, adding optionality to its dermatology pipeline
Almirall SA ($GB:0O9B) announced an update on their ongoing clinical study. Study Overview: Almirall S.A. is running a phase 2 trial called “A ...
TipRanks on MSN
MicroPort NeuroTech steps up competition in brain vascular devices with new embolic agent trial
MicroPort NeuroTech Limited ($HK:2172) announced an update on their ongoing clinical study. Study Overview The clinical study “a Prospective, ...
Pfizer Inc (PFE) announced an update on their ongoing clinical study.
The gray-market drugs flooding Silicon Valley reveal a community that believes it can move faster than the F.D.A.
Treadmill and outdoor walking offer similar benefits for physical and mental health. The best choice is one that fits your ...
China NMPA approves GSK’s Nucala to treat adults with chronic obstructive pulmonary disease: London, UK Tuesday, January 6, 2026, 10:00 Hrs [IST] GSK plc announced that China’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback